Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
Combining therapies like scyllo-inositol, alpha-ketoglutarate, and autophagy-inducing supplements may enhance hair growth and prevent hair loss. Reporting individual results can accelerate progress in hair loss treatments.
Baldness is not an evolutionary disadvantage because it occurs after reproductive age. Treatments like Minoxidil and Finasteride are used for androgenetic alopecia but don't address the root cause.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.